AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
A phase 1/2 trial of AB-2100 in renal cell carcinoma, run by Arsenal Biosciences, Inc., active and no longer recruiting.
Overview
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) is a phase 1/2 interventional study registered as NCT06245915 by Arsenal Biosciences, Inc., with 37 participants enrolled, started 2024-02-26 and due to reach its primary completion in 2026-03-31. Interventions recorded: AB-2100.
Similar pages
not linked directly; found by shared links- TrialAB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Shares Arsenal Biosciences and the tag pipeline.
- TrialStudy of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Shares Renal cell carcinoma and the tag pipeline.
- TrialPhase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Shares Renal cell carcinoma and the tag pipeline.
- TrialA Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Shares Renal cell carcinoma and the tag pipeline.
- TrialA Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Shares Renal cell carcinoma and the tag pipeline.
- TrialTT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Shares Renal cell carcinoma and the tag pipeline.
- TrialA Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
Shares Renal cell carcinoma and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Shares Renal cell carcinoma and the tag pipeline.